Avacta Group, a developer of Affimer biotherapeutics and reagents, announced that it will launch an ELISA laboratory test for the SARS-CoV-2 spike protein to support global research efforts into the ...
Avacta Group plc, the developer of Affimer ® biotherapeutics and reagents, is pleased to announce that it will launch an ELISA laboratory test for the SARS-CoV-2 spike protein to support global ...
Dublin, Dec. 05, 2025 (GLOBE NEWSWIRE) -- The "ELISA Test Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" has been added to ResearchAndMarkets.com's offering. The ...
Scientists say they have developed a new computational method to reduce variability in common research biomarker tests. They see their techniques as a promising step in improving the ability of ...
Enzyme-linked immunosorbent assays (ELISAs) represent the gold standard for quantitatively detecting protein biomarkers, and are used for applications such as diagnosing or monitoring disease, ...
CAMBRIDGE & WETHERBY, England--(BUSINESS WIRE)--Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it will launch an ELISA laboratory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback